PDCD1 and non-small cell lung carcinoma: In a retrospective study of patients with non-small cell lung cancer (NSCLC) treated with anti-PD-1, pre-existing ANA, rheumatoid factor (RF), anti-thyroiglobulin and anti-thyroid peroxidase antibodies positivity correlated with the development of irAEs but also with clinical benefit from ICI immunotherapy (91).